BioBalance Announces New Subsidiary Board.

Business Editors/Health/Medical Writers

NEW YORK--(BUSINESS WIRE)--Feb. 11, 2004

The BioBalance Corp., a wholly owned subsidiary of New York Health Care (Nasdaq: BBAL), announced today that it has established a new four member Board of Directors. Working with management, the new board intends to utilize their experience and contacts in the pharmaceutical industry as part of BioBalance's efforts to accelerate the development and licensing of its lead biotherapeutic agent, PROBACTRIX(TM) for various gastrointestinal disorders. The members of the board are John Nugent of Short Hills, NJ, Steven Francesco of South Orange, NJ, Dennis O'Donnell, the President and COO of BioBalance, and New York Health Care director H. Gene Berger.

"We are extremely pleased that John Nugent and Steve Francesco have agreed to join me and Gene Berger on this new board" said Mr. O'Donnell. "These individuals bring to the Company a wealth of pharmaceutical experience and public company expertise. BioBalance will greatly benefit from the proven leadership and broad management experience of these individuals as we continue to move toward commercialization of our lead product."

Nugent, age 61, is a seasoned executive with over 30 years of consumer packaged goods and pharmaceutical experience. Most recently, he was Founder and CEO of Eagle Family Foods. Prior to that, he was President of several Johnson & Johnson companies, including Ortho Dermatological and J&J Consumer Products. Mr. Nugent has served on a number of boards and professional organizations and has an MBA from the University of Chicago. He served in the U.S. Army in Vietnam and was awarded two Bronze Stars and the Air Medal, and rose to the rank of Captain.

Francesco, age 54, is President and Founder of Francesco International, which provides pharmaceutical management consulting in areas such as strategic planning, business transactions and market intelligence. He is a recognized expert on pharmaceutical life cycle management and has testified as an expert many times before the U.S. Food and Drug Administration (FDA). Previously, Mr. Francesco headed the international divisions of Schering Plough and Sterling Drug. In total, he has over 20 years of management experience in the pharmaceutical industry. He has an MBA from Columbia University.

Berger, age 63, has been a director of New York Health Care since February 1998. Since 1981, Mr. Berger has been president of Jay Isle Associates, a healthcare consulting firm. Previously, he held senior management positions at Pfizer and other healthcare companies.

The BioBalance Corporation

BioBalance is a development stage specialty pharmaceutical company focused on the discovery, development and commercialization of proprietary treatments for gastrointestinal (GI) disorders including irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis and various diarrheas caused by antibiotics, chemotherapy or AIDS. BioBalance operates as a wholly owned subsidiary of New York Health Care, a home healthcare company with which it merged on January 2, 2003. Additional information regarding BioBalance, which is not part of this press release, is located on its website at www.thebiobalancecorp.com.

SAFE HARBOR STATEMENT In addition to historical information, certain of the statements in the preceding paragraphs, particularly those anticipating future events, financial performance, business prospects and growth and operating strategies constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as anticipate, believe, estimate, expect, intend, predict, hope or similar expressions. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements, including, without limitation, satisfaction of approvals and conditions applicable to the transaction described above, the company's ability to implement its strategies and achieve its objectives and the risks and uncertainties described in reports filed by the company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation, cautionary statements made in New York Health Care's 2002 Annual Report on Form 10-K, its Form S-4 Registration Statement, its latest quarterly report on Form 10-Q and current reports on Form 8-K.